---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-057876"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-05-15T20:41:12+00:00"
generated_at: "2026-05-15T21:05:18.045473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology

## Summary
- Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.
- Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.
- Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.
- Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.
- First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T.

## SEC filing metadata
- accession: 0001213900-26-057876
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-05-15T20:41:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/0001213900-26-057876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea0291037-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-057876
- JSON: https://secwatch.observer/filing/0001213900-26-057876.json
- Plain text: https://secwatch.observer/filing/0001213900-26-057876.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported fiscal second quarter ended March 31, 2026 results: revenue Net product revenues of $1.7 million for the three months ended March 31, 2026.
  - Period: fiscal second quarter ended March 31, 2026
  - Revenue: Net product revenues of $1.7 million for the three months ended March 31, 2026
  - Result: reported results
  source text: Net product revenues of $1.7 million for the three months ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/0001213900-26-057876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.